Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The company purchased Metsera in November for up to $10 billion to reignite its ...

Explore groundbreaking research on ALS and how a specific mouse strain could change its study and treatment forever.

AI and machine learning are revolutionizing drug discovery, development, and lifecycle management, addressing industry ...

Continuous process improvement can benefit all aspects of life — from personal New Year’s resolutions to complex drug development. In a world where two-thirds of planned improvement initiatives fail, ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

Pawankumar Suresh enhances early-stage drug research processes, ensuring regulatory compliance through effective systems and vendor governance.

Early-stage regulatory strategy is becoming a powerful driver of speed, risk reduction, and commercial value in drug ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

This episode of the Pharmaron DMPK Insights Podcast Series sees Simon Taylor (Vice President of Drug Discovery at Pharmaron) and Dr. Emile Chen (former Director of Modeling and Translational Biology ...

The FDA has proposed cutting fees for early-stage companies conducting clinical development in the U.S. instead of abroad. The proposal is designed to incentivize U.S. drug development by tacking on ...